June 2025 | Issue:06

Veeda™ Lifesciences

THE VEEDA NEWSLETTER

Science, Strategy and Collaboration on the Global Stage

With strong engagement across global events, Veeda deepened its footprint in biotech, regulatory science and oncology research.

Read More

Inside Veeda Group: June 2025

info@veedalifesciences.com
www.veedalifesciences.com

Excellence In Everything

From the CEO's DESK

Veeda™ Lifesciences

Scaling Science with Purpose: Veeda Lifesciences' Vision for Biotherapeutic Innovation

This June, our journey through **BIO International Convention 2025, 30th European Hematology Association (EHA) Congress** and **CPHI China** have reaffirmed a belief I hold deeply: the future of medicine will be shaped not just by scientific progress, but by our ability to scale that science with purpose and intention.

At BIO 2025, we engaged with biotech leaders to showcase Veeda Lifesciences' integrated biopharma platform, spanning discovery biology, preclinical R&D, bioprocess development, analytical sciences and clinical bioanalysis. From fusion proteins and biosimilars to Protacs and vaccines, our teams demonstrated how we apply cutting-edge tools like high-resolution mass spectrometry and SPR to meet the analytical demands of next-generation biologics.

At EHA 2025, we shared our research on novel trial strategies in multiple myeloma, while reinforcing our capabilities in immunogenicity, neutralising antibody assays, cytokine profiling and biomarkers, key enablers in hematologic biotherapy development. And at CPHI China, we strengthened ties with global manufacturing networks, spotlighting our regulatory strength, backed by over **140 inspections** from authorities such as **USFDA, EMA, ANVISA** and **MHRA,** and a legacy of **5,300+ studies.**

As we look ahead, Veeda Lifesciences will continue to invest in future-ready technologies and forge collaborations that drive meaningful progress. Through our expanding biotherapeutic capabilities and collaborative approach, we continue to support healthcare innovation that truly serves patients and advances science with integrity.

Warm Regards,
Dr. Mahesh Bhalgat
Group CEO & MD, Veeda Lifesciences

Veeda Voice

Insights and Connections from BIO US 2025

Veeda joined global leaders in Boston, exchanging ideas and strengthening ties across the drug development spectrum from preclinical to clinical.

EHA 2025 Highlights Veeda's Hemato-Oncology Focus

At EHA 2025, Veeda reinforced its dedication to myeloma and blood cancer research through strategic engagement and scientific exchange.

Expanding Pharma Partnerships at CPHI China 2025

Veeda engaged with global pharma leaders in Shanghai, opening doors for impactful collaborations and innovative opportunities.



Peptide ADA Assay Case Study Unveils Smart Testing Strategy

Veeda's tailored approach to peptide ADA assay development showcased accuracy, regulatory alignment, and scientific depth in immunogenicity testing.

Industry INSIDER

Veeda™ Lifesciences

Gene therapy and rapid test seen as a new hope for sickle cell disease, say medical experts

High-tech gene therapy with affordable diagnostic tools is seen to be a groundbreaking leap for sickle cell disease (SCD) care in India. This is a part of the Union government's plan in its ambitious mission to eliminate the disease by 2047, India's 100th year of independence.

Read More

Macquarie University's new study shows DNA 'glue' could help prevent and treat age related disorders

Macquarie University new study could hold the key to developing therapies for devastating age-related diseases such as motor neuron disease (MND), Alzheimer's disease, and Parkinson's disease.

Read More

EMA Recommends Approval for Bayer's Nubeqa in Advanced Prostate Cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) for marketing authorization in the European Union (EU), for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Read More

Saptalis Launches Fluoxetine Oral Solution for Mental Health Treatment

Hauppauge-Headquartered Saptalis Pharmaceuticals, a rapidly growing company focused on the development, manufacturing, and commercialization of specialty pharmaceutical products, has announced the commercial launch of fluoxetine oral solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively.

Read More



WHO issues first global guideline to improve pregnancy care for women with sickle cell disease

The World Health Organization (WHO) released its first-ever global guideline on the management of sickle cell disease (SCD) during pregnancy, addressing a critical and growing health challenge that can have life-threatening consequences for both women and babies.

Read More

Industry INSIDER

Veeda™ Lifesciences

Immuno Cure and PharmaJet Partner on Needle-Free HIV DNA Vaccine

Immuno Cure BioTech, a clinical-stage biotechnology group based in Hong Kong Science Park, announced its upcoming collaboration with PharmaJet to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered through PharmaJet's innovative Tropis needle-free injection system in a clinical study.

Read More

EMA Supports Zemcelpro, Cordex Biologics' Stem Cell Therapy for Blood Cancer

European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) for Zemcelpro (dorocubicel/unexpanded umbilical cord cells) to treat adults with haematological malignancies (blood cell cancers).

Read More

US FDA Clears Lomond's IND for Lonitoclax in Relapsed AML Patients

Lomond Therapeutics Holdings, Inc. (Lomond Therapeutics), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of haematological malignancies, announced that the US Food and Drug Administration (FDA) has cleared it's Investigational New Drug (IND) application for a phase 1 multicenter study

Read More

Utopia Therapeutics Raises $1.5M to Advance Obesity Vaccine Development

Utopia Therapeutics, a biotech company developing next-generation vaccines for chronic metabolic diseases, announced it has secured seed funding of $1.5 million investment from Whale Tank, a leading early-stage venture firm focused on breakthrough life science innovations. The announcement was made at the BIO International Convention 2025.

Read More

Micropep and Corteva Collaborate on Next-Gen Peptide Biocontrol Solutions

Micropep Technologies, a global leader in micropeptide technology for sustainable crop protection, in partnership with Corteva, Inc, a global pure-play agriculture technology company, both jointly announced a multi-year research and development collaboration through its Corteva Catalyst platform to co-develop next-generation peptide-based biocontrol solutions.

Read More

Employee SPOTLIGHT

Veeda™ Lifesciences

Welcoming New Faces at Veeda Europe

New joiners from Marousi and beyond connected in person and virtually to kick off their Veeda journey with warmth and collaboration.

Ajit Amritkar Shares Expertise at Shimadzu UFMS 2025

At the Shimadzu UFMS Community 2025 in Ahmedabad, Ajit delivered an insightful talk on sustainable and rapid bioanalysis using advanced SFC-MS/MS technology.

Read More!

Celebrating Birthdays with Thoughtful Gestures

Team members marked their special day with cheerful moments and thoughtful gift vouchers, a small gesture of appreciation from the Veeda family.

Regulatory AFFAIRS

Veeda™ Lifesciences

CDSCO Releases Draft Guidelines on Similar Biologicals

The Central Drugs Standard Control Organization (CDSCO) has released new Draft Guidelines on Similar Biologicals, aligning with global standards such as those from the US-FDA and EMA. The guidelines emphasize structural and biological similarity, in-vitro and PK/PD studies, and include provisions for waiving animal and Phase 3 studies under specific conditions. Veeda has actively contributed scientific inputs to support faster biosimilar approvals and improved patient access.

US-FDA Approves Lenacapavir for HIV Prevention

The US-FDA has approved Gilead's Lenacapavir, a long-acting injection to be administered twice yearly for HIV prevention. This represents a significant breakthrough in HIV/AIDS care, offering a more convenient and effective prevention option for at-risk populations.

CDSCO Publishes Pharmacovigilance Guidelines for MA Holders

CDSCO has published new Pharmacovigilance Guidelines for Marketing Authorisation Holders, aimed at strengthening post-marketing drug safety monitoring in India. Dr. Kiran Marthak was among the key contributors to these guidelines, underscoring Veeda's continued commitment to regulatory excellence and patient safety.

US FDA Approves Blood Test for Early Alzheimer's Detection

The US FDA has approved the first-ever blood test for early-stage detection of Alzheimer's disease, marking a major advancement in neurodiagnostic tools and offering hope for earlier intervention.

info@veedalifesciences.com

www.veedalifesciences.com

Regulatory AFFAIRS

Veeda™ Lifesciences

Address:

Corporate Office

VEEDA CLINICAL RESEARCH LIMITED
Satyamev House, Nr. Shalin Bunglow,
Prahladnagar, Ahmedabad 380015

Registered Office

Shivalik Plaza-A, Near IIM Ambawadi,
Ahmedabad- 380015, Gujarat, India. CIN
No. U73100GJ2004PTC044023

Global Offices

- India
- Greece
- Italy
- Ireland

info@veedalifesciences.com
www.veedalifesciences.com

Excellence In Everything